|
Match
|
Document |
Document Title |
|
|
6482987 |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
Novel, stable formulations of bupropion hydrochloride are provided which will maintain at least 80% of initial bupropion hydrochloride potency after one year. Methods of inhibiting degradation of...
|
|
|
6482434 |
Method for reducing adverse effects of a weight loss regimen
A method for reducing certain effects associated with a negative calorie balance in a human includes the step of administering conjugated linoleic acid to a human in an amount effective to reduce...
|
|
|
6475779 |
Polymeric gene delivery
A means for obtaining efficient introduction of exogenous genes into a patient, with long term expression of the gene, is disclosed. The gene, under control of an appropriate promoter for...
|
|
|
6475521 |
Biphasic controlled release delivery system for high solubility pharmaceuticals and method
A biphasic controlled release delivery system for pharmaceuticals which have high water solubility, such as the antidiabetic metformin HCl salt, is provided which provides a dosage form that has...
|
|
|
6468560 |
Controlled release dosage form of &lsqb R-(Z)&rsqb -α-(methoxyimino)-α-(1-azabicyclo&lsqb 2.2.2&rsqb oct-3yl) acetonitrile monohydrochloride
A controlled release formulation of an acetonitrile compound and its use in the treatment and/or prophylaxis of certain disorders.
|
|
|
6468959 |
Peroral dosage form for peptide containing medicaments, in particular insulin
There is provided a plural dosage form for peptide pharmaceuticals comprising a matrix of gelatin or gelatin derivative having distributed therein the peptide pharmaceutical in particular insulin,...
|
|
|
6461641 |
Tumor delivery vehicles
The major problem with current direct delivery techniques of therapeutic reagents into solid tumors, especially of cells or large volumes of recombinant DNA reagents or drugs, has been resistance...
|
|
|
6458384 |
Pharmaceutical with predetermined activity profile
A first pharmacologically active substance contained in a pharmaceutical, which acts on a specific biological function, is released according to a predetermined release profile (D.1), FIG. 1, and...
|
|
|
6451342 |
Core formulation comprised of troglitazone and a biguanide
This invention relates to a controlled release combination drug product comprising troglitazone, e.g. its hydrochloride, and a biguamide, e.g. metformin. In particular, the product comprises a core...
|
|
|
6451341 |
Time release formulation of vitamins, minerals and other beneficial supplements
The present invention concerns a formulation of vitamins, minerals and other beneficial supplements which has been demonstrated to be cancer-protective. It is believed that the formulations of the...
|
|
|
6451345 |
Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
The present invention provides taste-masked microcapsules of Linezolid or the like (any member of the orally effective oxazolidinone or macrolide antibiotics), suitable for oral administration as a...
|
|
|
6451343 |
Composition for treating dementia and Alzheimer's disease
Controlled release dosage forms useful in the treatment and/or prophylaxis of dementia, including Alzheimer's disease, in mammals, and for enhancing amyloid precursor protein processing along a...
|
|
|
6451848 |
Compositions and methods comprising morphine gluconate
The present invention relates to a pharmaceutical composition which includes morphine gluconate or chemical equivalent thereof. In one embodiment, the present invention includes a method of making...
|
|
|
6447807 |
Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery
A method for making the potassium and sodium salts of (−)-hydroxycitric acid and mixtures thereof workable, non-hygroscopic and non-reactive in acidic media by encasement in hydrophobic and...
|
|
|
6447797 |
Antibacterial phosphoinositides
It has been discovered that certain phosphoinositides demonstrate antibacterial activity. Particularly, these phosphoinositides have been discovered to prevent the adhesion of H. influenzae onto...
|
|
|
6444221 |
Methods of treating chronic inflammatory diseases using carbonyl trapping agents
These and other objects of this invention are achieved by providing a novel method and compositions for the clinical treatment of chronic inflammatory diseases. This invention involves use of...
|
|
|
6440458 |
Sustained release preparations
Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in...
|
|
|
6440457 |
Method of administering antidepressant dosage form
The invention pertains to a dosage form 10 and to administering an antidepressant medicament 16 for an extended period of time in a rate-known dose.
|
|
|
6440459 |
Paroxetine maleate polymorph and pharmaceutical compositions containing it
The form B of paroxetine maleate polymorph is characterized by determined data of X ray diffraction: it has a chemical stability which is superior to that of the form A of paroxetine maleate. This...
|
|
|
6436438 |
Tramadol multiple unit formulations
A multiple unit oral pharmaceutical dosage form having a plurality of pellets in a water soluble capsule or in a tablet compressed from the pellets, wherein each pellet contains (a) a substantially...
|
|
|
6432446 |
Non-arrhythmogenic metabolite of oxybutynin
A method of treating disorders involving the urethrogentical tract by administering to pateints in need therof therapeutically effective amounts of the desethyl metabolite of oxybutynin and/or the...
|
|
|
6432447 |
Organic compounds
An oral dosage form comprising fluvastatin and HPMC, which oral dosage form is color-stable upon prolonged periods of storage.
|
|
|
6428810 |
Pharmaceutical formulation comprising omeprazole
An enteric coated oral pharmaceutical formulation comprising as active ingredient a compound selected from the group of omeprazole, an alkaline salt of omeprazole, one of the single enantiomers of...
|
|
|
6426091 |
Sustained-release theophylline tablet
A theophylline sustained release tablet obtained by coating core granules composed mainly of theophylline with a layer of a coating film composed of a hydrophobic material and a plastic excipient...
|
|
|
6423340 |
Method for the treatment of inflammatory bowel diseases
Described herein are methods comprising the oral administration of budesonide for the treatment of ulcerative colitis and Crohn's colitis in its active phase. The methods can also be applied as...
|
|
|
6419959 |
Galenic composition containing opioid antagonists
A pharmaceutical composition for oral administration contains naloxone-, N-methylnaloxone- and/or N-methylnaltrexone-containing particles which release the active substance depending on the ambient...
|
|
|
6416786 |
Sustained release tablet containing hydrocolloid and cellulose ether
The present invention is directed to a solid sustained release pharmaceutical tablet for administering to a host, comprising a therapeutically effective amount of a pharmaceutically active...
|
|
|
6413941 |
Polymer composition for delivering a nucleic acid or derivative thereof
A composition for delivering a biologically active polyanionic molecule comprising a linear polymer with a backbone comprising amido and tertiary amino groups arranged regularly on the backbone and...
|
|
|
6410052 |
Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
The invention described herein encompasses a methods and compositions of treating cancer or solid tumors comprising the administration of a therapeutically effective amount of catechins, a group of...
|
|
|
6410517 |
Targeted gene delivery system
A target-specific gene delivery system is made of enzymatically degradable gelatin and nucleic acids (DNA or RNA) microparticles with a linking moiety or a targeting ligand attached to the surface....
|
|
|
6406716 |
Anticonvulsant containing composition for treating neuropathic pain
The effectiveness of an anticonvulsant such as gabapentin for alleviating neuropathic pain is potentiated by a nontoxic antagonist for the N-methyl-D-aspartate receptor or nontoxic substance that...
|
|
|
6399096 |
Pharmaceutical formulation
A solid, oral controlled release pharmaceutical dosage form has a water-soluble active ingredient dispersed in a matrix and releases the active ingredient at such a rate upon administration that...
|
|
|
6399100 |
Controlled release pharmaceutical compositions containing tiagabine
Controlled release oral pharmaceutical preparations are provided which comprise a therapeutically effective amount of tiagabine or a pharmaceutically acceptable salt thereof dispersed in a rate...
|
|
|
6391341 |
Gastroresistant multi-unitary pharmaceutical preparations containing piroxicam
The present invention relates to multi-unitary pharmaceutical preparations containing piroxicam for oral administration. Such pharmaceutical preparations are stable pellet pharmaceutical...
|
|
|
6387403 |
Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine...
|
|
|
6379700 |
Process for manufacturing tablets for the sustained release of active principle(s)
The invention concerns a method for making tablets with active principle sustained-release which consists in: preparing a fluid oil-in-water emulsion; spraying the resulting emulsion on a powder...
|
|
|
6372252 |
Guaifenesin sustained release formulation and tablets
The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a...
|
|
|
6372255 |
Tablet for instant and prolonged release of one or more active substances
A multi-layer tablet for the instant and prolonged release of active substances comprises at least two layers where the first outer layer comprises a mixture of excipients and an active substance,...
|
|
|
6368625 |
Orally disintegrable tablet forming a viscous slurry
A dosage form which rapidly disintegrates in the mouth and forms a viscous slurry of either microcapsules or a powder is described. The rapidly disintegrating dosage form is meant for direct oral...
|
|
|
6368638 |
Process of making an aqueous calcium carbonate suspension
The present invention relates to a high dosage calcium carbonate aqueous antacid pharmaceutical suspension for oral use, and methods of preparation.
|
|
|
6365185 |
Self-destructing, controlled release peroral drug delivery system
The present invention relates to tablets which are time-controlled to release active agent at different rates in different regions of the digestive tract in order to maintain a substantially...
|
|
|
6365173 |
Stereocomplex polymeric carriers for drug delivery
A polymeric carrier for delivery of bioactive or bioreactive molecules is provided, including a stereocomplex of one or more biocompatible polymers and having incorporated on or within the complex...
|
|
|
6365183 |
Method of fabricating a banded prolonged release active agent dosage form
The present invention is directed to an active agent dosage form and methods of its fabrication which is useful for the prolonged delivery of an active agent formulation to a fluid environment of...
|
|
|
6365182 |
Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet
The present invention relates to a potassium containing dosage form which is capable of rapidly disintegrating in a patient's mouth to form an easy to swallow slurry.
|
|
|
6358525 |
Sustained release polymer blend for pharmaceutical applications
A pharmaceutical composition has a blend of at least first and second components and a medicament in a sufficient amount to be therapeutic where the first component is hydroxypropylcellulose (HPC)...
|
|
|
6355272 |
Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharamaceutical compositions
A complex between carrageenan and a water soluble drug characterized in powder form having an average particle size comprised between 10 and 100 μm, and the basic water drug is contained in the...
|
|
|
6350471 |
Tablet comprising a delayed release coating
The invention provides a delayed release tablet, comprising: (i) a core comprising an active ingredient selected from the group consisting of oxybutynin hydrochloride, propranolol hydrochloride,...
|
|
|
6348216 |
Ibuprofen and narcotic analgesic compositions
Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising...
|
|
|
6346268 |
Sustained release formulation containing three different types of polymers and tablet formed therefrom
Depot drug formulations include the pharmaceutical itself and a three component release rate controlling matrix composition. The three components of the matrix composition are (1) a pH dependent...
|
|
|
6346270 |
Phenytoin therapy
A therapeutic composition, a dosage form and a method are disclosed for administering phenytoin indicated for the management of epilepsy.
|